New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections
February 2011
New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections.
A beta-lactam (cephalexin, etc) USED to cover both purulent skin infections due to staph and cellulitis due to strep.
But now most staph skin infections are due to community-acquired methicillin-resistant Staph aureus (CA-MRSA) and therefore are resistant to beta-lactams.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote